We Create Innovative Galenic Forms That Improve Compliance
Our team develops innovative carrier forms that ensure the arrival of viable strains to their sites of action. To do this, we strive to better understand strain behavior through downstream processes and their resistance to biological stresses during digestion. Our goal is to create innovative probiotic forms that contribute to better health. We achieve this by developing finished products that meet specific administration routes and market needs, expanding Lallemand’s expertise segments. Some examples of our ongoing projects include the Healthy Aging and the Women’s Health Programs that require the exploration of specific dosage forms for these specific populations. Each product containing newly developed strains is accompanied by tailored analysis, method development and scale-up, supported by the efforts of the Bioprocess and Galenic Expertise Platform from the start all the way through the production of the first commercial batches. Throughout this process, we make sure that our products are optimized for ease of consumption.
Understanding Strain Behavior
Our approach involves understanding strain behavior through downstream processes, including but not limited to shelf-life and compression resistance, down to their site of action. To improve strain availability in a specific host site, we study strain digestion resistance and explore novel ways to administer probiotics, such as vaginal routes or viscous liquids tailored to specific populations. Additionally, we provide factory support to ensure a seamless production chain from the fermenter to delivery.
We are exploring protective technologies to better protect sensitive strains from physiological challenges. Rather than reacting to behavior, we value prediction and anticipation and develop internal tools for the screening of strains and finished products. Our goals include developing innovative forms—such as candyceutic formulations to counter pill-fatigue—and expanding our portfolio to encompass historically challenging galenic forms. Our team also investigates alternative routes of administration to better target oral and women’s health and designs specific galenic forms tailored for distinct population needs, including older adults.
Leveraging Innovative Technologies
Our team leverages innovative technologies and tools to enhance our research. We are always in search of new excipients and formulation technologies adapted to the specific needs of our ever-evolving strain portfolio. This includes anticipating future needs based on ongoing development from other R&D platforms. The development of next-generation probiotics (NGPs) leads us to explore specific manufacturing conditions to ensure strains survival in finished products. Enumeration methods are also developed for finished products since each new formula requires enumeration method customization for specific matrices and excipients. Every year, we partner with start-ups and sub-contractors who have their own expertise to assess new probiotic applications. In recent years, we introduced four new formulation bases to the market and tested eighteen formulas at an industrial pilot scale.